drugset / Trial / NCT04476628

Efficacy of Budesonide Via Delayed Release vs Immediate Release

NCT04476628

Phase 0 Withdrawn St. Paul's Hospital, Canada
RandomizedCrossoverSingle-blindTreatment

Summary

The aim of this study is to compare the efficacy of intranasal budesonide administration with lying head back position and a 5 mins time to release of medication (5MR) compared to 1 min time to release (1MR) in chronic rhinosinusitis patients (CRS). Participants will be instructed to administer via mucosal automatization device (MAD) with either of the two treatment approaches daily for 5 to 7 days per week and 8 weeks total. This is a crossover study design so each participants will be placed in the other treatment approach for an additional 8 weeks of treatment. Moreover, there will be a "washout" of 2 weeks after baseline assessment and before the first treatment, as well as a second "washout" of 2 weeks between the two treatment approaches. The participants will also complete study related procedures such as endoscopic evaluation, cultures, and two questionnaires throughout the study period. The investigators hypothesize that Budesonide delivered to the sinuses with a 5 minute time to release of medication will be more effective at decreasing inflammation when compared to a 1 minute time to release of medication after administration.

Timeline

Start
2021-02-01
Primary completion
2022-01-31
Completion
2022-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Budesonide Small molecule Intranasal